Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FOLH1 | Q04609 | 1/20 | 0.48 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.48 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.45 |
| ▸ | MME | P08473 | 6/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.45 |
| ▸ | ACE | P12821 | 7/20 | 0.44 |
| ▸ | CPA1 | P15085 | 1/20 | 0.44 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 2/20 | 0.43 |
| ▸ | CA2 | P00918 | 2/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3082077 | 0.79 | CA1 (0.46) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL3082072 | 0.79 | CA1 (0.46) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL31398551 | 0.78 | FOLH1 (0.52) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL3983123 | 0.78 | FOLH1 (0.59) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL3983134 | 0.78 | FOLH1 (0.59) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL9847993 | 0.76 | FOLH1 (0.54) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL5738141 | 0.76 | FOLH1 (0.61) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL9847998 | 0.76 | FOLH1 (0.54) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL12869808 | 0.76 | FOLH1 (0.61) | FOLH1NAALAD2SLC7A5MMEMEN1 | |
| SCHEMBL55972 | 0.76 | FOLH1 (0.56) | FOLH1NAALAD2SLC7A5MMEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8486885-B2 | β-arrestin effectors and compositions and methods of use thereof | TREVENA, INC. (US) | 2013-07-16 | — | — | US | disclosed |
| US-20100184701-A1 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof | TREVENA, INC. | 2010-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100184701-A1 | Beta-Arrestin Effectors And Compositions And Methods Of Use Thereof | ARRB1, ADRB1, ADRB3 | FOLH1 4437/4885NAALAD2 2569/4885SLC7A5 4709/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.